<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395199</url>
  </required_header>
  <id_info>
    <org_study_id>AmloThal RCT</org_study_id>
    <nct_id>NCT01395199</nct_id>
  </id_info>
  <brief_title>Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major</brief_title>
  <acronym>AmloThal</acronym>
  <official_title>Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the use of amlodipine, a drug that blocks the uptake of
      calcium into cells, in the prevention and treatment of iron overload in patients with
      thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and
      other organs, blocking these channels might help to prevent the accumulation of iron in these
      tissues. The study will follow 60 patients with thalassemia major: 30 will receive amlodipine
      and 30 will serve as controls receiving placebo in a randomized double-blind fashion.
      Patients will be monitored through one year. Monitoring will occur through the measurement of
      blood ferritin as well as live and heart T2* by MRI initially, at 6 and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial T2* values (msec)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>T2* values represent the amount of iron in the myocardial and is quantified in msec and measured by cardiovascular magnetic resonance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver T2* values (msec)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>T2* values represent the amount of iron in the liver and is quantified in msec and measured by cardiovascular magnetic resonance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum ferritin levels</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricle volumes and function</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Thalassemia</condition>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Starch pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5mg PO initially; may be reduced to 2.5mg PO if side effects</description>
    <arm_group_label>Starch pill</arm_group_label>
    <arm_group_label>Amlodipine</arm_group_label>
    <other_name>norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with thalassemia major with at least 6 years of age undergoing iron chelation
             therapy.

          2. No anticipated changes in chelation regimen for the next 12 months

          3. Completed and signed Informed Consent

        Exclusion Criteria:

          1. Pregnancy

          2. Advanced class III/IV heart failure or LVEF &lt; 0.35% (by MRI)

          3. Formal contra-indications to MRI (pacemakers, cerebral aneurysm metal clips, etc).

          4. Advanced heart AV block
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliano L Fernandes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13100000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.abrasta.org.br/</url>
    <description>Brazilian Thalassemia Association</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Juliano de Lara Fernandes</investigator_full_name>
    <investigator_title>Physician Researcher</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Thalassemia</keyword>
  <keyword>Iron overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

